EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

U2Bio Co., Ltd. (221800) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of U2Bio Co., Ltd. KRW 1,606, price KRW 3,625, upside -55.7%, quality 33 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

UC Thin data Sep 24, 2026

U2Bio Co., Ltd.

221800 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 1,606 KRW · Strongly overvalued (−56%)
!Quality 33/100
!Weak Growth (revenue 3y −28.2 %/yr)
!Loss-making · -6.4% net margin (TTM)
!Low debt · negative free cash flow
·2.76% dividend yield
!Trails peers (2/9)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
!Weak on future: 1 out of 100
Watch U2Bio Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

28,200 KRW 2,298 KRW Fair Value 1,606 KRW Nov 2023 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

35‑month range 2,298 KRW – 28,200 KRW · fair‑value band 1,060 KRW – 2,007 KRW · the 3,625 KRW price screens above the 1,606 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow U2Bio Co. in your weekly email

Every Wednesday you see whether U2Bio Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ZGOO Holdings Co., Ltd. provides healthcare services in South Korea. The company also offers specimen testing services; digital healthcare services related to testing and health examinations; and bio-technology platforms. The company was formerly known as U2Bio Co., Ltd. and changed its name to ZGOO Holdings Co., Ltd. in April 2026.

Show more

ZGOO Holdings Co., Ltd. provides healthcare services in South Korea. The company also offers specimen testing services; digital healthcare services related to testing and health examinations; and bio-technology platforms. The company was formerly known as U2Bio Co., Ltd. and changed its name to ZGOO Holdings Co., Ltd. in April 2026. The company was founded in 2009 and is headquartered in Seoul, South Korea.

Stock analysis

U2Bio Co., Ltd. (221800) currently trades at 3,625 KRW, while our model-based Fair Value estimate is 1,606 KRW, implying the stock looks roughly 125.7% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 3 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 1,060 KRW (bear) to 2,007 KRW (bull), the price of 3,625 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

U2Bio Co., Ltd. reported revenue of 25.6B KRW in FY2025 versus 50.6B KRW in FY2021, a compound −15.6%/yr. Reported net income was −1.6B KRW in FY2025.

Key figures

Market cap 78.2B KRW (≈ $57.4M) · P/S ratio 3.05 · Dividend yield 2.8% · Net margin −6.4% · Return on equity −4.3% · Return on assets (EBIT) 7.7% · Operating margin −13.4% · Revenue (TTM) 25.6B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 87% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −56%, 221800 screens richer than that median.

Fair Value models

Bear 1,060 KRW Fair Value 1,606 KRW Bull 2,007 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Gordon GGM 144.53 KRW 154.47 KRW 169.11 KRW 67
DDM Multi-Stage 144.53 KRW 167.29 KRW 195.68 KRW 65
NCAV (Graham) 1,296 KRW 1,737 KRW 2,592 KRW 54
All 3 models by family
Dividend Discount
Gordon GGM 144.53 KRW 154.47 KRW 169.11 KRW 67
DDM Multi-Stage 144.53 KRW 167.29 KRW 195.68 KRW 65
Asset-Based
NCAV (Graham) 1,296 KRW 1,737 KRW 2,592 KRW 54

Open the full fair value analysis →

Notify me when 221800 reaches fair value

Put 221800 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 33/100

Of which business quality 36 · Market factors (momentum, volatility) 24

Profitability 12
Margins and returns on capital today
Quality Growth 45
Are margins and returns improving?
Cashflow 10
Earnings quality: real cash, not paper profit
Fin. Strength 77
Balance sheet, leverage, solvency risk
Investment 86
Disciplined investing over empire-building
Low Volatility 20
Calm price path (market factor)
Momentum 23
Price trend over the last 3–12 months (market factor)
52W Momentum 29
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−28.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
17.9% (2021) → −8.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

221800 screens 126% overvalued. Compare with Thermo Fisher Scientific Inc →

Compare U2Bio Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −56% · Below median
Profitability
Return on assets −3% · Below median
Net margin (TTM) −6% · Below median
Operating margin (TTM) −13% · Below median
Growth and dividend
Revenue growth 0% · Below median
Dividend yield (TTM) 2.8% · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)1 · sector 28
PAST (return on equity)0 · sector 8
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)55 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $678.39 $686.04 +1%
Danaher Corporation DHR $223.77 $209.18 −7%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 570.00 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $522.02 $495.84 −5%
Agilent Technologies, Inc A $165.32 $63.90 −61%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $255.38 $280.92 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

U2Bio Co., Ltd. · Fair Value
1,606 KRW −126%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "U2Bio Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/221800

Frequently asked questions

Is U2Bio Co., Ltd. (221800) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,606 KRW versus a price of 3,625 KRW, about −56% upside (overvalued).
What is the fair value of 221800?
Our model-based fair value for U2Bio Co., Ltd. is 1,606 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,625 KRW.
What is the quality score of 221800?
U2Bio Co., Ltd. has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for U2Bio Co., Ltd. (221800)?
Our model-based price target is the fair value of 1,606 KRW (as of Sep 24, 2026) from 3 valuation models. Cautious scenario 1,060 KRW, optimistic scenario 2,007 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the U2Bio Co., Ltd. stock forecast for 2026?
Our models put fair value at 1,606 KRW, about −56% upside versus a price of 3,625 KRW (overvalued). Cautious scenario 1,060 KRW, optimistic scenario 2,007 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of U2Bio Co., Ltd. (221800)?
U2Bio Co., Ltd. reported trailing-twelve-month revenue of about 25.6B KRW (latest available figure, as of Sep 24, 2026).
Does U2Bio Co., Ltd. pay a dividend?
U2Bio Co., Ltd. currently shows a dividend yield of about 2.76% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of U2Bio Co., Ltd. (221800)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For U2Bio Co., Ltd. it is 1,606 KRW per share (as of Sep 24, 2026), against a price of 3,625 KRW. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is U2Bio Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 221800 trades above its calculated fair value: price 3,625 KRW, fair value 1,606 KRW, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 221800?
No. The price is what the market pays today (3,625 KRW); the fair value is what the company's own numbers justify (1,606 KRW). For U2Bio Co., Ltd. the two are 2,019 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is U2Bio Co., Ltd. worth?
The market values U2Bio Co., Ltd. at about 78.2B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,625 KRW; our models calculate a fair value of 1,606 KRW per share.
What do the bullish and bearish scenarios say about 221800?
Our models span a range for U2Bio Co., Ltd.: cautious scenario 1,060 KRW, base 1,606 KRW, optimistic 2,007 KRW per share (as of Sep 24, 2026, price 3,625 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of U2Bio Co., Ltd. (221800)?
Balance-sheet figures for U2Bio Co., Ltd. (as of Sep 24, 2026): return on equity −4.3%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is 221800 from its 52-week high?
U2Bio Co., Ltd. trades at 3,625 KRW, about 87% below its 52-week high of 28,200 KRW and 16% above the low of 3,118 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,606 KRW is for.
Which stocks are comparable to U2Bio Co., Ltd.?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is U2Bio Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 3,625 KRW, calculated fair value 1,606 KRW (−56%), Quality Score 33/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 221800 calculated?
We run U2Bio Co., Ltd. through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,606 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. U2Bio Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of U2Bio Co., Ltd. (221800)?
The closing price on Sep 23, 2026 was 3,625 KRW. Our model-based fair value is 1,606 KRW, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with U2Bio Co., Ltd. right now?
The price sits above even our optimistic bull case (2,007 KRW). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1,060 KRW to 2,007 KRW) leaves room in how you read the outcome.

Key figures of U2Bio Co., Ltd.

How large is the market capitalisation of U2Bio Co., Ltd. (221800)?
The market capitalisation of U2Bio Co., Ltd. is 78.2B KRW (≈ $57.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of U2Bio Co., Ltd. (221800)?
The price-to-sales ratio of U2Bio Co., Ltd. is 3.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of U2Bio Co., Ltd. (221800)?
The dividend yield of U2Bio Co., Ltd. is 2.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of U2Bio Co., Ltd. (221800)?
The net margin of U2Bio Co., Ltd. is −6.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of U2Bio Co., Ltd. (221800)?
The return on equity (ROE) of U2Bio Co., Ltd. is −4.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of U2Bio Co., Ltd. (221800)?
On an EBIT basis the return on assets of U2Bio Co., Ltd. is 7.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of U2Bio Co., Ltd. (221800)?
The operating margin of U2Bio Co., Ltd. is −13.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at U2Bio Co., Ltd. (221800)?
Revenue at U2Bio Co., Ltd. is growing +0.1% versus a year earlier (3y avg −28.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does U2Bio Co., Ltd. (221800) generate?
The free cash flow of U2Bio Co., Ltd. is −1.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch U2Bio Co., Ltd. in the live analysis

One click puts U2Bio Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.